| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $866,999 | 5 | 100 |
Sells | $0 | 0 | 0 |
| KERSTEN GEERT R | Chief Executive Officer | 5 | $866,999 | 0 | $0 | $866,999 |
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, …
Over the last 12 months, insiders at CEL-SCI Corporation have bought $866,999 and sold $0 worth of CEL-SCI Corporation stock.
On average, over the past 5 years, insiders at CEL-SCI Corporation have bought $389,205 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: KERSTEN GEERT R (Chief Executive Officer) — $866,999.
The last purchase of 100,000 shares for transaction amount of $138,000 was made by KERSTEN GEERT R (Chief Executive Officer) on 2026‑08‑25.
| 2026-08-25 | KERSTEN GEERT R | Chief Executive Officer | 100,000 1.3569% | $1.38 | $138,000 | +10.81% | ||
| 2026-05-14 | KERSTEN GEERT R | Chief Executive Officer | 300,000 4.03% | $1.20 | $360,000 | +14.62% | ||
| 2026-05-13 | KERSTEN GEERT R | Chief Executive Officer | 100,000 1.4431% | $1.19 | $119,000 | +23.75% | ||
| 2026-01-22 | KERSTEN GEERT R | Chief Executive Officer | 38,023 0.4598% | $5.26 | $200,001 | -74.42% | ||
| 2025-12-04 | KERSTEN GEERT R | Chief Executive Officer | 8,389 0.1164% | $5.96 | $49,998 | -72.34% | ||
| 2025-07-25 | KERSTEN GEERT R | Chief Executive Officer | 29,197 0.3576% | $6.85 | $199,999 | -37.20% | ||
| 2025-07-25 | Watson Robert Eugene | director | 2,919 0.0357% | $6.85 | $19,995 | -37.20% | ||
| 2024-05-08 | KERSTEN GEERT R | Chief Executive Officer | 30,000 0.0556% | $1.39 | $41,700 | -43.53% | ||
| 2024-05-08 | PRICHEP PATRICIA B | Senior Vice President | 8,000 0.0148% | $1.39 | $11,120 | -43.53% | ||
| 2024-05-08 | Watson Robert Eugene | director | 20,000 0.0371% | $1.39 | $27,800 | -43.53% | ||
| 2021-10-19 | Sale | TALOR EYAL | Chief Scientific Officer | 15,000 0.0345% | $11.25 | $168,750 | -63.02% | |
| 2021-07-06 | KERSTEN GEERT R | Chief Executive Officer | 25,000 0.0615% | $8.00 | $200,000 | -9.69% | ||
| 2021-07-06 | BAILLAVOINE BRUNO JEAN-MARIE | director | 1,250 0.0031% | $8.00 | $10,000 | -9.69% | ||
| 2021-07-06 | Watson Robert Eugene | director | 1,250 0.0031% | $8.00 | $10,000 | -9.69% | ||
| 2021-06-28 | YOUNG PETER R | director | 3,000 0.0068% | $12.66 | $37,971 | -44.12% | ||
| 2021-04-22 | Sale | CIPRIANO JOHN | Senior Vice President | 10,000 0.0244% | $24.38 | $243,793 | -62.09% | |
| 2020-12-11 | YOUNG PETER R | director | 100 0.0003% | $14.24 | $1,424 | -8.02% | ||
| 2020-11-18 | BAILLAVOINE BRUNO JEAN-MARIE | director | 800 0.0021% | $11.77 | $9,416 | +16.45% | ||
| 2020-11-18 | Watson Robert Eugene | director | 800 0.0021% | $11.77 | $9,416 | +16.45% | ||
| 2020-11-17 | YOUNG PETER R | director | 800 0.0021% | $11.68 | $9,343 | +16.15% |
| KERSTEN GEERT R | Chief Executive Officer | 316142 1.7974% | $445,760.22 | 36 | 0 | +14.55% |
| PRICHEP PATRICIA B | Senior Vice President | 232326 1.3209% | $327,579.66 | 7 | 0 | <0.0001% |
| ZIMMERMAN DANIEL H | Senior Vice President | 114387 0.6503% | $161,285.67 | 5 | 3 | +23.45% |
| TALOR EYAL | Chief Scientific Officer | 104899 0.5964% | $147,907.59 | 4 | 16 | |
| CIPRIANO JOHN | Senior Vice President | 63108 0.3588% | $88,982.28 | 3 | 5 | |
| YOUNG PETER R | director | 28914 0.1644% | $40,768.74 | 13 | 2 | +35.12% |
| BAILLAVOINE BRUNO JEAN-MARIE | director | 5973 0.034% | $8,421.93 | 3 | 0 | +10.07% |
| Watson Robert Eugene | director | 3733 0.0212% | $5,263.53 | 5 | 0 | <0.0001% |
$156,891,025 | 80 | -24.91% | $36.3M | |
$121,435,814 | 28 | 12.32% | $33.53M | |
CEL-SCI Corporation (CVM) | $931,435 | 28 | 16.31% | $24.8M |
$226,127 | 22 | -27.62% | $21.96M | |
$352,389 | 18 | 9.66% | $17.82M |
| Increased Positions | 20 | +50% | 130,130 | +14.87% |
| Decreased Positions | 14 | -35% | 263,112 | -30.06% |
| New Positions | 10 | New | 77,498 | New |
| Sold Out Positions | 6 | Sold Out | 3,828 | Sold Out |
| Total Postitions | 46 | +15% | 742,207 | -15.19% |
| Vanguard Group Inc | $1,507.00 | 3.66% | 292,563 | +109,352 | +59.69% | 2025-09-30 |
| Commonwealth Equity Services, Llc | $902.00 | 2.19% | 175,209 | +175,209 | New | 2025-09-30 |
| Blackrock, Inc. | $701.00 | 1.7% | 136,087 | +21,842 | +19.12% | 2025-09-30 |
| Mai Capital Management | $396.00 | 0.96% | 76,861 | +11,928 | +18.37% | 2025-09-30 |
| Geode Capital Management, Llc | $313.00 | 0.76% | 60,751 | +34,833 | +134.4% | 2025-09-30 |
| Bank Of America Corp /De/ | $211.00 | 0.51% | 40,978 | -3 | <0.01% | 2025-09-30 |
| State Street Corp | $120.00 | 0.29% | 23,270 | +23,270 | New | 2025-09-30 |
| Osaic Holdings, Inc. | $89.00 | 0.22% | 17,323 | +1,793 | +11.54% | 2025-09-30 |
| Ubs Group Ag | $80.00 | 0.19% | 15,524 | -14,293 | -47.94% | 2025-09-30 |
| Northern Trust Corp | $73.00 | 0.18% | 14,205 | +14,205 | New | 2025-09-30 |